로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CD19

CD19

요약

Name:B-lymphocyte antigen CD19
Target Synonym:Differentiation antigen CD19,CD19 Molecule,B-Lymphocyte Surface Antigen B4,CD19 Antigen,B-Lymphocyte Antigen CD19,CVID3,B4,Antigens, CD19,CD19,T-cell surface antigen Leu-12
Number of Launched Drugs:9
Number of Drugs in Clinical Trials:181
Lastest Research Phase:Phase 3 Clinical

라이센싱

항목 적응증 연구 단계 합작 수요
BIA202202 Autoimmune diseases/ B cell malignancies Apply for IND License-out or co-development
BPR202201 NHL, Leukemia Pre-clinical License-out or co-development
BEN202201 Autoimmune disease FDA IND Ready License-out or co-development

제품 리스트 비교 또는 구매

제품번호 제품 설명 구조 순도 특징
CD9-H82F6 Human Biotinylated Human CD19 (20-291) Protein, Fc,Avitag™, premium grade
CD9-H82F6-structure
CD9-H82F6-sds
CD9-M52H8 Mouse Mouse CD19 Protein, His Tag
CD9-M52H8-structure
CD9-M52H8-sds
CD9-HA2H7 Human Alexa Fluor 555-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HA2H7-structure
CD9-HA2H5 Human APC-Labeled Human CD19 (20-291) Protein, His Tag (Site-specific conjugation)
CD9-HA2H5-structure
CHEK-ATS056 Human HEK293/Human Anti-CD19 Stable Cell Line
CD9-HA2H9 Human APC-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HA2H9-structure
CD9-HP2H5 Human PE-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HP2H5-structure
CD9-R52H6 Rat Rat CD19 Protein, His Tag
CD9-R52H6-structure
CD9-R52H6-sds
CD9-C52H4 Canine Canine CD19 Protein, His Tag
CD9-C52H4-structure
CD9-C52H4-sds
CD9-R52H3 Rabbit Rabbit CD19 Protein, His Tag
CD9-R52H3-structure
CD9-R52H3-sds
CD9-HF2H3 Human FITC-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HF2H3-structure
CD9-HF2H3-sds
CD9-C5221 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, His Tag
CD9-C5221-structure
CD9-C5221-sds
MBS-K005 Human Human CD19-coupled Magnetic Beads
CD9-H82E9 Human Biotinylated Human CD19 (20-291) Protein, His,Avitag™ (SPR verified) DMF Filed
CD9-H82E9-structure
CD9-H82E9-sds
CD9-HP2H3 Human PE-Labeled Human CD19 (20-291) Protein, His Tag (Site-specific conjugation) DMF Filed
CD9-HP2H3-structure
CD9-H5258 Human Human CD19 (20-291) Protein, Mouse IgG2a Fc Tag
CD9-H5258-structure
CD9-H5258-sds
CD9-HF251 Human FITC-Labeled Human CD19 (20-291) Protein, Fc Tag DMF Filed
CD9-HF251-structure
CD9-HF251-sds
CD9-HF2H2 Human FITC-Labeled Human CD19 (20-291) Protein, His Tag DMF Filed
CD9-HF2H2-structure
CD9-HF2H2-sds
CD9-H5251 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity, MALS verified) DMF Filed
CD9-H5251-structure
CD9-H5251-sds
CD9-H5250 Human Human CD19 (20-291) Protein, Llama IgG2b Fc Tag, low endotoxin
CD9-H5250-structure
CD9-H5250-sds
CD9-H52H2 Human Human CD19 (20-291) Protein, His Tag DMF Filed
CD9-H52H2-structure
CD9-H52H2-sds
CD9-C5251 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, Fc Tag
CD9-C5251-structure
CD9-C5251-sds
CD9-H8259 Human Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling) DMF Filed
CD9-H8259-structure
CD9-H8259-sds
CD9-H5259 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin
CD9-H5259-structure
CD9-H5259-sds

일부의 생물활성 데이터

CD9-HA2H7-Cell-based assay
Evaluation of CAR expression

5e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 10 μg/mL of AF555-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HA2H7), and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF555 signal was used to evaluate the binding activity (QC tested).

CD9-H82E9-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human CD19 (20-291), His,Avitag (Cat. No. CD9-H82E9) captured on Biotin CAP - Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.255 nM as determined in a SPR assay (Biacore 8K) (QC tested).

CD9-H5251-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) captured on CM5 chip via Anti-Human lgG Fc antibodies surface, can bind FMC63 MAb (Mouse lgG2a) with an affinity constant of 0.17 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

사용자 리뷰

Synonym Name

CD19,B4,CVID3,MGC12802

Background

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Brexucabtagene autoleucel KTE-X19; FKC-889 Approved Kite Pharma Inc, Gilead Sciences Inc Tecartus EU Lymphoma, Mantle-Cell Kite Pharma Eu Bv 2020-07-24 Lymphoma, Mantle-Cell Details
Axicabtagene ciloleucel FKC-876; KTE-C19; KTE C19 Approved Cabaret Biotech, Gilead Sciences Inc Yescarta, 奕凯达 Mainland China Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, B-Cell Fosun Kite Biotechnology Co Ltd 2017-10-18 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Lisocabtagene maraleucel Liso-Cel; JCAR-017 Approved Fred Hutchinson Cancer Research Center, Juno Therapeutics, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute Breyanzi EU Mediastinal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Bristol-Myers Squibb Pharma Eeig 2021-02-05 Lymphoma, B-Cell; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Mediastinal Neoplasms; Immune System Diseases; Lymphoma, Follicular; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma Details
Tafasitamab XmAb-5574; MOR-208; XENP-5574; MOR-00208 Approved Xencor MONJUVI EU Lymphoma, Large B-Cell, Diffuse Incyte Biosciences Distribution Bv 2020-07-31 Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Loncastuximab tesirine ADCT-402 Approved Adc Therapeutics Lonca, ZYNLONTA United States Lymphoma, Large B-Cell, Diffuse Adc Therapeutics Sa 2021-04-23 Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Tisagenlecleucel CART-019; CTL-019; CART-19; LG-740 Approved Novartis Pharma Ag, University Of Pennsylvania Kymriah EU Lymphoma, Follicular Novartis Europharm Ltd 2017-08-30 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell Details
Relmacabtagene autoleucel JWCAR-029 Approved Suzhou Yaomingjunuo Biotechnology Co Ltd 倍诺达, Carteyva Mainland China Lymphoma, Large B-Cell, Diffuse Jw Therapeutics (Shanghai) Co Ltd 2021-09-01 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Inebilizumab 16C4-aFuc; MEDI-551; MT-0551; VIB-0551 Approved Duke University, Horizon Therapeutics Plc Uplizna, ユプリズナ, Uplinza EU Neuromyelitis Optica Horizon Therapeutics Ireland Dac 2020-06-11 Lymphoma, B-Cell; Hematologic Neoplasms; Myasthenia Gravis; Rejection of renal transplantation; Immunoglobulin G4-Related Disease; Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica; Encephalitis Details
Blinatumomab MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3; AMG-103 Approved Amgen Inc Blincyto, 倍利妥 Mainland China Precursor Cell Lymphoblastic Leukemia-Lymphoma Amgen Inc 2014-12-03 Neoplasm, Residual; Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
4G7SDIE Clinical Synimmune, The University Of Tubingen Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) Phase 1 Clinical University Hospitals Cleveland Medical Center Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase 1 Clinical Ut Southwestern Medical Center Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
aCD19z aCD19z Phase 1 Clinical Christie Hospital Nhs Foundation Trust Lymphoma, Non-Hodgkin Details
PTG-01 PTG-01 Phase 1 Clinical Protheragen Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
H-31970-SAGAN H-31970-SAGAN Phase 1 Clinical Baylor College Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD20 CAR-T Cell Therapy (PersonGen) Phase 1 Clinical Details
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) Clinical Leidos Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-CAR CD19-CAR Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Leukemia; Lymphoma Details
Virus-specific-CD19.CAR Phase 1 Clinical Baylor College Of Medicine Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
CD19.CAR-VST CD19.CAR-VST Phase 1 Clinical Baylor College Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) Phase 2 Clinical Wuhan Bio-Raid Biotechnology Hematologic Diseases; Lymphoma, B-Cell Details
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) Phase 1 Clinical Nagoya University, Shinshu University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) PZ-01 Clinical Pinze Lifetechnology Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CLIC-1901 (Ottawa Hospital Research Institute) CLIC-1901 Phase 2 Clinical Ottawa Hospital Research Institute Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Leukemia, Lymphoid Details
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) Phase 1 Clinical Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) yinnuokati-19 Phase 2 Clinical Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) XLCART-001 Phase 2 Clinical Nanjing Medical University Lymphoma, B-Cell Details
3rd-gen-CD19-CAR 3rd-gen-CD19-CAR Phase 2 Clinical Bluebird Bio Lymphoma, B-Cell; Leukemia, B-Cell Details
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) BPX-401 Phase 2 Clinical Bellicum Pharmaceuticals, Ospedale Pediatrico Bambino Gesu Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) WZTL002-1 Phase 1 Clinical The Malaghan Institute Of Medical Research Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin Details
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) Phase 1 Clinical City Of Hope National Medical Center Lymphoma, Non-Hodgkin Details
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) CARCIK-CD19; CIK-CAR.CD19 Phase 2 Clinical Fondazione Matilde Tettamanti Menotti De Marchi Onlus Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase 1 Clinical Henan Provincial Cancer Hospital Lymphoma, B-Cell Details
U-CART (Shanghai Bioray Laboratory Inc) Phase 2 Clinical Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 2 Clinical The First Affiliated Hospital Of Nanchang University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
Anti-CD19 CAR-T cell therapy (Sinobioway) Phase 2 Clinical Sinobioway Biomedicine Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma Details
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) Phase 1 Clinical Beijing Yongtai Rec Biotechnology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19 CAR-T cell therapy (National University of Malaysia) Phase 3 Clinical National University Of Malaysia Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CART-19 cells (Henan Hualong Biotechnology) Phase 2 Clinical Henan Hualong Biotechnology Leukemia, Lymphoid Details
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital Leukemia Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase 1 Clinical Shanghai Jiaotong University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) Phase 1 Clinical Kunming Medical University Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy GC-197 Phase 2 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19 CAR-T (HuaDao CAR-Tcell) Phase 1 Clinical Huadao (Shanghai) Biopharma Co Ltd Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
K-193 K-193 Phase 1 Clinical Beijing Lvzhu Biological Technology Co Ltd Lymphoma, B-Cell Details
CN-201 CN-201 Phase 1 Clinical Tongrun Biomedicine (Shanghai) Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
CLBR-001/SWI-019 CLBR-001/SWI-019 Phase 1 Clinical Abbvie Inc, California Institute For Biomedical Research Lymphoma, B-Cell Details
KUR-502 CD19 CAR-NKT KUR-502; CMD-502 Phase 1 Clinical Athenex Inc Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Autologous CAR19 T lymphocytes Therapy Phase 1 Clinical Institute of Hematology and Blood Transfusion, Czech Republic Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CAR-T-19 Cell Therapy (The General Hospital Of The People'S Liberation Army) Phase 1 Clinical The General Hospital Of The People'S Liberation Army Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
NCAR19-T Phase 2 Clinical Second Military Medical University Of Chinese People'S Liberation Army Lymphoma, B-Cell Details
UCART019 UCART-019 Phase 2 Clinical The General Hospital Of The People'S Liberation Army Lymphoma, B-Cell; Leukemia, B-Cell Details
TanCART19/20 Phase 1 Clinical The General Hospital Of The People'S Liberation Army Neuromyelitis Optica Details
19273-4SCAR 19273-4SCAR Phase 2 Clinical Peking University Lymphoma, B-Cell Details
4-1BBz CD19-Her2tG (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Neoplasms Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma Details
MCM-998 MCM-998; LXG-250 Phase 1 Clinical Novartis Pharma Ag Multiple Myeloma Details
CC-312 CC-312 Phase 1 Clinical Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Leukemia; Lymphoma Details
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) Phase 1 Clinical Aikangd Biomedical Technology (Suzhou) Co Ltd Leukemia; Lymphoma Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) CAR-20/19-T cells Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase 1 Clinical Stanford University Lymphoma, B-Cell Details
Ensomafusp alfa RG-6076 Phase 1 Clinical F. Hoffmann-La Roche Ltd Details
Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center) Phase 1 Clinical City Of Hope National Medical Center Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR CD19/79b Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell Details
JCAR-014 JCAR-014 Phase 2 Clinical Fred Hutchinson Cancer Research Center, Juno Therapeutics, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) Fred Hutchinson Cancer Research Center Details
CTA-101 CTA-101 Phase 1 Clinical Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) Phase 2 Clinical Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University Lymphoma, B-Cell; Leukemia, B-Cell Details
Obexelimab XmAb-5871; AMG-729 Xencor Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) Hebei Senlang Biological Technology Co Ltd Details
SGN-CD19B SGN-CD19B Seattle Genetics Inc Details
Acmucabtagene autoleucel TAC01-CD19; TAC-921; CD19-TAC01 Triumvira Immunologics Details
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells TAK-940 Takeda Neoplasms Details
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) Phase 1 Clinical First Affiliated Hospital Of Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
Murine CD19 CAR-T cell therapy (Yake) Shanghai YaKe Biotechnology Co Ltd Details
PBLTT52CAR19 Phase 1 Clinical Great Ormond Street Hospital For Children Nhs Foundation Trust Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
GC019F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
Anti-human CD19-CD22 T cell therapy Phase 1 Clinical Hrain Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
FT-819 FT-8198; FT-819 Phase 1 Clinical Fate Therapeutics Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Multiple Myeloma Details
CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University) Phase 2 Clinical Nanfang Hospital Of Southern Medical University Leukemia, Biphenotypic, Acute Details
CTA-30X CTA30X; CTA-30X Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) HX-s001; YTS101; HX-s001/YTS101; HXYT-001 Phase 1 Clinical Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
C-CAR039 EXP-039; C-CAR039; C-CAR-039 Phase 1 Clinical Cellular Biomedicine Group Ltd Lymphoma, Non-Hodgkin Details
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) Phase 1 Clinical Wuhan Union Hospital Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anbalcabtagene autoleucel CRC-01 Curocell Inc Details
RPM CD19-mbIL15-CAR-T cell therapy (Eden BioCell) Details
RGV-004 RGV-004 Phase 1 Clinical Hangzhou Rongu Biotechnology Co Ltd Lymphoma, B-Cell Details
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) CT-120 Phase 2 Clinical Nanjing Iaso Biotherapeutics Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
ThisCART-19 ThisCART-19 Fundamenta Therapeutics Ltd Details
FT-596 FT-596 Phase 1 Clinical Fate Therapeutics Inc Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Obecabtagene autoleucel AUTO1; Obe-cel; AUTO-1 University College London Details
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) Phase 1 Clinical University Of Colorado, Denver, Usa Lymphoma, Non-Hodgkin Details
GC-502 GC-502 Gracell Biotechnologies (Shanghai) Co Ltd Details
ALLO-501A ALLO-501A Allogene Therapeutics Inc Details
Allogeneic CD-19 CAR-T Cell Therapy Shenzhen University General Hospital Details
Bispecific CD19/22 CAR T cells Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
IMJ-995 IMJ-995 Novartis Pharma Ag Details
SNUH-CD19-CAR-T Cell Therapy SNUH-CD19-CAR-T Seoul National University Hospital Details
CD19-UCART CD-19-UCART; CD19-UCART Phase 1 Clinical Bioray Laboraytories Inc Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital Details
BinD-19 (Shenzhen BinDeBio) BinD-19 Shenzhen Bindebio Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Azercabtagene zapreleucel PBCAR-0191 Phase 2 Clinical Baxalta Hematologic Neoplasms; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin Details
C-CAR011 Pla General Hospital Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
ALLO-501 ALLO-501 Cellectis Details
KITE-363 KITE-363 Phase 1 Clinical Kite Pharma Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse Details
CD19-CART (Unicar-Therapy Bio-medicine Technology) Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
YTB-323 YTB-323 Phase 2 Clinical Novartis Pharma Ag Lymphoma, Large B-Cell, Diffuse Details
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory) Bioray Laboraytories Inc Details
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) ssCART-19 Phase 1 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
HuCART19 National Cancer Institute, Kite Pharma Details
Coltuximab ravtansine SAR-3419; huB4-DM4 Immunogen Details
TC-110 TC-110 Tcr2 Therapeutics Details
CC-97540 CC-97540 Juno Therapeutics Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) The First Affiliated Hospital Of Nanchang University Details
GC-012F GC-012F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Lymphoma, Non-Hodgkin Details
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) University Of Alberta Details
Anti-CD19 CAR T-cell therapy (University College London) 4G7-CARD University College London Details
Humanized CD19 CAR-T cell therapy (Yake) YK-C19 Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Leukemia, Lymphoid Details
Anti-CD19 CAR T cell therapy (Shanghai GeneChem) Shanghai Genechem Co Ltd Details
CD19.CAR T Cells (University Hospital Heidelberg) University Of Heidelberg Details
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) Xuanwu Hospital Of Capital Medical University Details
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) Xinqiao Hospital, Army Medical University Details
XYF19 CAR-T Cell Therapy XYF-19 Xi'An Yufan Biotechnology Co Ltd Details
CAR-CD19 T cell therapy Phase 2 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Lymphoma, Non-Hodgkin Details
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) Fujian Medical University Details
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-19 Shenzhen Geno-Immune Medical Institute Details
AMG-562 AMG-562 Amgen Inc Details
TG-1801 NI-1701; TG-1801 Novimmune Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase 1 Clinical Chengdu Yinhe Biomedicine Co Ltd, Beijing Mali Biotechnology Co Ltd Lymphoma, B-Cell Details
pCAR-19B Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) Hrain Biotechnology Details
AFM-11 AFM-11 Affimed Details
CD19 CAR-T cell therapy (Chongqing Precision Biotech) Chongqing Precision Biotechnology Co Ltd Details
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) Shanghai Zhongshan Hospital, Hrain Biotechnology Details
Evoncabtagene pazurgedleucel CTX-110 Crispr Therapeutics Details
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) Chaim Sheba Medical Center At Tel Hashomer Details
GC007g GC-007G Phase 2 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
MDX 1342 MDX-1342 Medarex Details
CAR-T 19 cell therapy (University of Pennsylvania) University Of Pennsylvania Details
A-319 A-319 Phase 1 Clinical Evive Biotech Ltd Lymphoma, B-Cell; Leukemia, B-Cell Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) The University Of Texas MD Anderson Cancer Center Details
IKS-03 IKS-03 Phase 1 Clinical Iksuda Therapeutics Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell Details
CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals) Phase 1 Clinical Sabz Biomedicals Leukemia, Biphenotypic, Acute Details
Anti-BCMA/CD19 CAR-T Therapy(University College London) Phase 1 Clinical University College London Multiple Myeloma Details
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) Phase 2 Clinical Kk Women'S And Children'S Hospital Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology) PL-001 Phase 2 Clinical Pell Bio-Med Technology Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma Details
GB5005 chimeric antigen receptor T cell therapy (Genbase) Phase 1 Clinical Shanghai Genbase Biotechnology Co Ltd Leukemia, B-Cell Details
CAR-20-19-22 CAR-20-19-22 Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) Phase 3 Clinical Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR-T cell therapy (Juventas) CNCT19; CNCT-19; HY001 Phase 2 Clinical Lymphoma, B-Cell; Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19 CARvac T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Lymphoma, B-Cell; Leukemia, B-Cell Details
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) Phase 1 Clinical Institute Of Hematology & Blood Diseases Hospital Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
TNB-486 TNB-486 Phase 1 Clinical Teneobio Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) Phase 1 Clinical University Of Colorado Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
ICT19G1 ICT-19G1 Phase 1 Clinical Innovative Cellular Therapeutics Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CTL-119 CTL-119 Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Multiple Myeloma Details
TI-1007 TI-1007 Phase 1 Clinical Tianjin Timmune Biotech Inc Lymphoma, B-Cell Details
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) 4SCAR19/22 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19-CAR-DNT cells Therapy(Zhejiang Ruijiamei Biotechnologies Co Ltd) Phase 1 Clinical Lymphoma, B-Cell Details
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) SENL-B19 Phase 2 Clinical Hebei Senlang Biological Technology Co Ltd Lymphoma, B-Cell; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma Details
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) Phase 1 Clinical Immune Cell Lymphoma, B-Cell; Leukemia, B-Cell Details
Anti-CD19 CAR-T cell therapy (Uppsala University) Phase 2 Clinical Uppsala University Lymphoma, B-Cell; Leukemia, B-Cell Details
ET190L1-ARTEMIS T cells (Eureka Therapeutics) ET190L1-ARTEMI; ET-190; ET190L1; ET190 Phase 1 Clinical Eureka Therapeutics Lymphoma, B-Cell; Leukemia, B-Cell Details
MB-CART19.1 (Miltenyi Biotec) Phase 2 Clinical Miltenyi Biotec Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
GC-007F (Gracell Biotechnology) GC-007F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19 chimeric antigen receptor T cell therapy (Takara Bio) TBI-1501 Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Takara Bio Inc Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Senl-1904A Senl-1904A; Senl_1904A Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Zamtocabtagene autoleucel MB-CART2019.1 Phase 2 Clinical Miltenyi Biotec Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
MC-19PD1 CAR-T cell therapy (Peking University) Phase 1 Clinical Peking University Lymphoma Details
ET-019002 ET-019002 Phase 1 Clinical Eureka Therapeutics Lymphoma, B-Cell; Neoplasms Details
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) Phase 2 Clinical Suzhou University Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation Details
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) Phase 1 Clinical Juno Therapeutics Leukemia, Lymphocytic, Chronic, B-Cell Details
GC-022 GC-022; GC-022F Phase 2 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) Phase 1 Clinical Tianjin Timmune Biotech Inc Leukemia Details
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Leukemia, Myeloid, Acute Details
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) Phase 1 Clinical Kecellitics Biotech Company Ltd Lymphoma Details
TAK-007 TAK-007 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Lymphoma, B-Cell Details
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Lymphoma, B-Cell; Leukemia, B-Cell Details
GNR-084 GNR-084 Phase 2 Clinical Generium Pharmaceuticals, Iontas Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) Phase 1 Clinical Memorial Sloan Kettering Cancer Center Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) Phase 1 Clinical The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-STAR-T cell therapy (China Immunotech Co Ltd) Phase 1 Clinical Hebei Yanda Hospital, China Immunotech Co Ltd Lymphoma, B-Cell Details
CD19-CART Phase 2 Clinical Hrain Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CAR-NK019(Second Affiliated Hospital, School of Medicine, Zhejiang University) Phase 1 Clinical Second Affiliated Hospital School Of Zhejiang University School Of Medicine Lymphoma, Non-Hodgkin Details
BZ019 BZ-019 Phase 2 Clinical Shanghai Cell Therapy Research Institute Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Multiple Myeloma; Lupus Erythematosus, Systemic Details
CD19/CD22 dual-target CAR-T (Yake biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-Engineered NK Cells therapy (Simnova) CAR-NK-CD19 Phase 1 Clinical Shanghai Simnova Biotechnology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
UCART-19 S-68587; UCART-19 Phase 1 Clinical Cellectis Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
RO-7227166 RO-7227166 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details
Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
IM19CAR-T Phase 2 Clinical Beijing Yimiao Medical Technology Co Ltd Hematologic Neoplasms; Leukemia; Neoplasms; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma Details
1-A-46 1-A-46; CMG1A46; CMG1A-46; BR110; 1A46 Phase 2 Clinical Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Emfizatamab GNC-038 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) Phase 1 Clinical Shanghai Cellular Biopharmaceutical Group Ltd Lymphoma, B-Cell Details
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) Clinical Nanjing Kati Medical Technology Co Ltd Neoplasms Details

This web search service is supported by Google Inc.

totop